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Proteomic analysis of conditioned media
from glucose responsive and glucose non-
responsive phenotypes reveals a panel of
secreted proteins associated with beta cell
dysfunction
Media conditioned by dysfunctioning pancreatic beta cells offer an excellent source of
potential protein markers associated with this phenotype. Proteins identified from cell
culture model systems are often found to be of importance clinically. Previous work by us
and others have shown that low-passage MIN-6 cells (MIN-6(L)) respond to changes in
glucose concentrations, producing an approximately 5.5-fold glucose-stimulated insulin
secretion (GSIS) in response to 26.7 mmol/L, compared with 3.3 mmol/L, glucose. After
continuous culture or high-passage (MIN-(H)), this GSIS was no longer present and thus
represents an excellent model system for investigating beta cell dysfunction. Employing
2-D difference gel electrophoresis and mass spectrometry a panel of protein markers
were identified in conditioned media (CM) from MIN-6(L) and MIN-6(H) beta cells.
These proteins, including secretogranin II, secretogranin III and transthyretin, are
associated with secretory granule biogenesis and were found to have substantially
increased levels in the CM from the non-responsive high-passage MIN-6 beta cells. A
panel of protein markers found to have increased abundance levels in CM from MIN-
6(H) compared with MIN-6(L) beta cells may have the potential to be used clinically for
assessing beta cell function and to monitor the effects of specific therapeutics.
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1 Introduction
Worldwide there are an estimated 150 million people
suffering from diabetes mellitus [1]. Each of these indivi-
duals is at a greater risk of developing a number of
complications, each of which is associated with a reduction
in quality of life and an increase in individual morbidity and
mortality. Two major concerns are that much of this
increase in diabetes will occur in developing countries,
due to population growth, ageing, unhealthy diets, obesity
and sedentary lifestyles, and that there is a growing
incidence of type II diabetes – which accounts for about
90% of all cases – at a younger age [2].
Type I diabetes is characterized by autoimmune
destruction of the insulin-producing beta cells in the islet of
Langerhans of the pancreas, whereas type II diabetes is
associated with reduced beta cell mass and function, as well
as insulin resistance [2]. To date, no reported panel of
circulating biomarkers indicative of beta cell function exists.
A panel of diabetes-specific biomarkers would be of great
benefit clinically and may aid in early detection and thera-
peutic monitoring of this disease.
MIN-6, a murine pancreatic beta cell line, that was
established from an insulinoma obtained by targeted
expression of the simian virus 40T antigen gene in trans-
genic mice has been widely used to investigate insulin
secretion [3, 4]. As a typical beta cell line, MIN-6 cells
express insulin and islet amyloid polypeptide. Previous work
by us and others have shown that low-passage MIN-6
cells respond to changes in glucose concentrations, produ-
cing an approximately 5.5-fold glucose-stimulated insulin
secretion (GSIS) in response to 26.7 mmol/L, compared
with 3.3 mmol/L, glucose. After continuous culture, this
GSIS was no longer present and thus represents
an excellent model system for investigating beta cell
dysfunction [5, 6].
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Beta cells are specialized for the secretion of insulin,
but they also secrete other hormones/factors and it is
likely that many of these proteins or their fragments may
eventually enter the circulation where they can be detected
[7, 8]. A number of studies have used a cell culture
model system where the cells were grown in serum-free
media to perform proteomic analysis [9]. The majority of
work on biomarker discovery using proteins identified
from conditioned media (CM) has focused on cancer
research. Many of these identified proteins have proven
to be very important as circulating serum biomarkers
[10]. To date, very little information exists on CM involving
pancreatic beta cells and thus remains an untapped
resource. We report here the discovery of proteins
associated with beta cell failure in CM from glucose-
responsive (low passage: L) and glucose-non-responsive
(high passage: H) cells using 2-D DIGE and mass
spectrometry.
2 Materials and methods
2.1 MIN-6 culture
MIN-6 cells (generously donated by Dr. Yamamoto,
Kumamoto University school of Medicine, Japan) were
grown in DMEM containing 20% heat-inactivated fetal calf
serum (FCS) and were cultured at 371C with 5% CO2.
Routine sterility checks, including screening for Mycoplas-
ma, indicated that the cells were clear of contamination.
MIN-6 (high passage/H) at passage 47 cells was established
by sub-culturing MIN-6 (low passage/L) cells from passage
37, as described previously [6].
2.2 Phase contrast light microscopy
MIN-6(L) and MIN-6(H) cells were cultured at 371C, 5%
CO2 for 5 days prior to analysis using phase contrast light
microscopy. This contrast-enhancing optical technique used
to produce high-contrast images of transparent specimens
was performed at 20magnification by imagining the
living, unfixed, cells using a Nikon Optiphot microscope
with phase contrast rings.
2.3 Preparation of serum-free CM
Cells were grown to 60–70% confluency in DMEM contain-
ing 20% heat-inactivated FCS and then washed three times
in serum-free medium. Cells were subsequently incubated
in serum-free medium for 1 h, washed two more times in
serum-free medium in order to remove any contaminating
bovine proteins from the FCS, and incubated in serum-free
media for 72 h. CM was collected, centrifuged at 1000 rpm
for 15 min to remove cellular debris, decanted into clean
tubes, and stored at 801C.
2.4 GSIS analysis of MIN-6 cells
MIN-6 cells were seeded at 2 105 cells/well in a 24-well
plate and were allowed to grow for 72 h prior to the GSIS
assay. Following this, 1KRB was prepared from an aliquot
of frozen 10 tock (36.525 g NaCl, 2.2 g KCl, 0.941 g
CaCl2  2H2O, 1.22 g MgCl2  6H2O, 29.8 g HEPES dissolved
in 500mL of H2O), BSA was added to a final concentration
of 0.1%, and the KRB-BSA was pH-adjusted to 7.36 at 191C
with 1 mol/L of NaOH. This solution was incubated for
30 min at 371C and 5% CO2. Glucose concentrations of 0,
3.3, 10, 16.7, and 26.7 mmol/L were prepared in the
conditioned 1KRB and were subsequently placed at
371C and 5% CO2 for 30 min. MIN-6 cells to be analyzed
were rinsed (twice) in 1KRB and were equilibrated at
3.3 mmol/L glucose for 30 min at 371C. After equilibration,
the glucose-containing stimulation media were added
(1 mL/well), incubated at 371C and 5% CO2 for 60 min.
The GSIS assay was then terminated by placing the plate on
ice. CM (500 mL) was removed from each well, placed in an
ice-cold Eppendorf tube, centrifuged at 2500 rpm for 5 min
and 200 mL of the supernatant was removed for analysis by
(pro)insulin ELISA (Mercodia, 10-1124-10;), following the
manufacturer’s instructions.
2.5 Sample preparation and protein labeling
CM from MIN-6(L) and (H) was concentrated using
3000 MW cut-off centricons (Millipore). The resulting
concentrate was processed using a 2-D Clean-Up kit
(Bio-Rad) to precipitate the proteins and remove any
contaminating elements. The precipitated protein pellet
was resuspended in lysis buffer containing (4%w/v CHAPS,
7 M urea, 2 M thiourea, 10 mM Tris-HCl, 5 mM
magnesium acetate of pH 8.5) and then placed in a
sonicating water bath for 15 min. Insoluble material
was removed by centrifugation at 14 000 rpm for 10 min at
room temperature. Protein concentration was deter-
mined using the Quick Start Bradford Protein Assay Kit
(Bio-Rad).
CM proteins were labeled with N-hydroxy succinimidyl
ester-derivatives of the cyanine dyes Cy2, Cy3, and Cy5
following the protocol described previously [11]. Typically,
50 mg of protein was minimally labeled with 200 pmol of
either Cy3 or Cy5 for comparison on the same
2-D gel. Labeling reactions were performed on ice in the
dark for 30 min and then quenched with a 50-fold molar
excess of free lysine to dye for 10 min on ice. A pool
containing equal amounts of all samples was also
prepared and labeled with Cy2 to be used as a standard
on all gels to aid image matching and cross-gel
statistical analysis. The Cy3 and Cy5 labeling reactions
(50 mg of each) from each lysate were mixed and run on the
same gels with an equal amount (50 mg) of Cy2-labeled
standard. The experimental was performed as described in
Table 1.
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2.6 Protein separation by 2-D gel electrophoresis
and gel imaging
Immobilized 24 cm non-linear pH gradient (IPG) strips (GE
Healthcare), pH 3–11, were rehydrated in rehydration buffer
(7 M urea, 2 M thiourea, 4% CHAPS, 0.5% IPG buffer,
50 mM DTT) overnight, according to the manufacturers’
guidelines (GE Healthcare). Isoelectric focusing was
performed using an IPGphor apparatus (GE Healthcare)
for a total of 40 kVh at 201C with resistance set at 50 mA.
Strips were equilibrated for 20 min in 50 mM Tris-HCl, pH
8.8, 6 M urea, 30%v/v glycerol, 1%w/v SDS containing
65 mM DTT and then for 20 min in the same buffer
containing 240mM iodoacetamide. Equilibrated IPG strips
were transferred onto 18 20-cm 12.5% uniform polyacry-
lamide gels poured between low fluorescence glass plates.
Strips were overlaid with 0.5%w/v low melting point
agarose in running buffer containing bromphenol blue.
Gels were run using the Ettan Dalt 12 apparatus (GE
Healthcare) at 2.5 W/gel for 30 min and then 100W total at
101C until the dye front had run off the bottom of the gels.
All the images were collected on a Typhoon 9400 Variable
Mode Imager (GE Healthcare). Statistics and quantitation of
protein expression were carried out in DeCyder software
(GE Healthcare).
2.7 Spot digestion and MALDI-TOF analysis
Excision of protein spots, trypsin digestion, and protein
identification by mass spectrometric analysis using an Ettan
MALDI-TOF Pro instrument from Amersham Biosciences
was performed according to an established methodology [5].
Preparative gels containing 300 mg of protein were fixed in
7.5% v/v acetic acid, 10% v/v methanol overnight. Gels were
washed with 4 10 min changes of DI water before total
protein was detected by post-staining with Deep Purple (GE
Healthcare) for 2 h at room temperature. To develop the
stain, 3 10min washed in 0.1% ammonia was performed
and subsequently the gels were washed in signal stabiliza-
tion solution (0.75% acetic acid) for a minimum of 10 min
before imaging. Gels were imaged using a Typhoon 9400
Variable Mode Imager (GE Healthcare) at the appropriate
excitation and emission wavelengths for the stain. The
subsequent gel image was imported into the BVA module of
DeCyder software and was matched to images generated
from DIGE analysis. Spots of interest were selected and
confirmed using this software for subsequent picking using
an Ettan Spot Picker. Gel plugs were subsequently destained
and washed using the Ettan Digester. The gel plugs were
rehydrated in digestion buffer (12.5 ng trypsin per mL of
10% acetronitrile, 40 mM ammonium bicarbonate) to cover
the gel pieces. More digestion buffer was added if all the
initial volumes had been absorbed by the gel pieces.
Exhaustive digestion was carried out overnight at 371C.
The supernatant was removed from each sample using the
Ettan Digester and the gel plug was washed a further two
times in 50% acetronitrile, 0.1% TFA and added to the
initial removed supernatant. Samples were then spotted
onto MALDI targets using an Ettan Spotter and mixed 1:1
with matrix solution (5 mg/mL a-cyano-4-hydroxycinnamic
acid in 50% acetonitrile/0.1% TFA v/v). Mass spectra were
recorded using the MALDI-TOF instrument operating in
the positive reflector mode at the following parameters:
accelerating voltage 20 kV; pulsed extraction: on (focus mass
2500). Internal and external calibration was performed
using trypsin autolysis peaks at m/z 842.50, m/z 2211.104
and Pep4 mix, respectively. The mass spectra were analyzed
using MALDI evaluation software (GE Healthcare), and
protein identification was achieved with the PMF Pro-Found
search engine for peptide mass fingerprints. Protein
identities were performed in triplicate from three indepen-
dent preparative gels. Search parameters for PMF included a
mass range of 0–300 kDa, enzyme used: trypsin, missed
cleavages: 1, modifications: 1C2H3ON@C(complete);
1O@M(partial), a charge state of MH1and a tolerance
(monoisotopic) of 0.10 Da.
2.8 Western blot analysis
An aliquot of 15 mg of protein was loaded onto a 12%
NuPAGE Bis-Tris Gels (Invitrogen) and electrophoretically
separated using a MOS/SDS buffer (Invitrogen). The
samples were run according to the manufacturer’s instruc-
tions (Invitrogen). Electrophoretic transfer of proteins to
Hybond-ECL nitrocellulose membranes (GE Healthcare)
was carried out using a Bio-Rad Transblot SD cell (BioRad).
Proteins were transferred for 50 min at 0.34 mA. The
efficiency of transfer was evaluated using Ponceau-S-Red
staining of nitrocellulose membranes, followed by destain-
ing in PBS (50 mM sodium phosphate, 0.9%w/v NaCl, pH
7.4). Membranes were blocked for 1 h in 5%w/v fat-free
milk powder in PBS containing 0.5% Tween-20.
Membranes were then incubated overnight at 41C with the
primary antibodies, secretogranin III; sc-1492 (Santa Cruz
Biotechnology) and transthyretin (TTR); Ab-9015 (Abcam) at
1:1000. Nitrocellulose replicas were subsequently washed
Table 1. Experimental design incorporating three independent
biological samples, technical replicates, and reverse
labelinga)
Gel Cy2 Cy3 Cy5
1 Pooled sample Min-6 LP#1 Min-6 HP#1
2 Pooled sample Min-6 LP#2 Min-6 HP#2
3 Pooled sample Min-6 LP#3 Min-6 HP#3
4 Pooled sample Min-6 HP#1 Min-6 LP#1
5 Pooled sample Min-6 HP#2 Min-6 LP#2
6 Pooled sample Min-6 HP#3 Min-6 LP#3
a) All samples employed in the experiment were used in the
Cy2-labeled internal pooled standard.
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twice for 10 min in blocking solution and then incubated
with corresponding peroxidase-conjugated secondary anti-
body (1:1000) for 1 h at room temperature. Nitrocellulose
membranes were washed twice for 10 min in blocking
solution and twice rinsed for 10 min in PBS. Visualization
of immuno-decorated 1-D bands was carried out using an
ECL kit (GE Healthcare). Blots with bound probes to
primary targets and associated secondary antibodies labeled
with horse radish peroxidase were placed in the ECL
substrate immediately after stringent washes. After the
2 min incubation period, the blots were exposed to X-ray
film for 30 s.
2.9 Statistical analysis
Student’s t-test was used to analyze differences in protein
levels from the CM of MIN-6(L) and MIN-6(H). A t-test
score of o0.01 was considered statistically significant.
3 Results
3.1 Morphology of MIN-6(L) and (H)
Phase contrast light microscopy indicates that MIN-6(L)
cells that are glucose-responsive tend to grow closely
together, forming discrete colonies (Fig. 1A), whereas
MIN-6(H) cells, shown in (Fig. 1B), which have lost their
glucose-responsiveness with culturing, appear to be more
disperse, stretched cells.
3.2 GSIS from MIN-6 low passage and high passage
cells
As shown in Fig. 2, MIN-6(L) cells secrete insulin in a
glucose-regulated manner, with an approximate. 5.5-fold
increase in secreted product between 3.3 and 26.7 mM
glucose. In contrast to this, MIN-6(H) cells do not show a
functional GSIS response i.e. the basal secretion of insulin
from these cells is not influenced by the glucose content of
their environment.
3.3 Proteomics analysis of media conditioned by
glucose-responsive and glucose-non-responsive
MIN-6 beta cells
Fifty micrograms of protein from each sample were labeled
with Cy2, Cy3, or Cy5. Samples each from MIN-6(L) and
MIN-6(H) medium and high cell densities (experimental
design included three independent biological samples/
technical replicates/reverse labeling) were labeled with Cy3
and Cy5, respectively (Table 1). All samples employed in the
experiment were used in the Cy2 labeled internal pooled
standard. Samples were combined and separated by 2-D gel
electrophoresis. For DeCyder image analysis, the differential
in-gel analysis mode of DeCyder was first used to merge the
Cy2, Cy3, and Cy5 images for each gel and to detect spot
boundaries for the calculation of normalized spot volumes/
protein abundance. At this stage, features resulting from
non-protein sources, namely dust particles and scratches,
A
Low passage (P- 37) High passage (P- 47) 
B
Figure 1. Phase contrast light micro-
scopy indicates that MIN-6(L) cells
(MIN-6 low passage cells), which are
glucose-responsive, tend to grow
closely together, forming discrete
colonies (A), whereas MIN-6(H)
cells (MIN-6 high passage cells),
shown in (B), which have lost their
glucose-responsiveness with cultur-
ing, appear to be more disperse,
stretched cells. Scale bar 200 mm.
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Figure 2. MIN-6(L) cells secrete (pro)insulin in a glucose-
regulated manner (hashed line). This regulated secretion is no
longer apparent following long-term culture/passaging of MIN-
6(H) cells (full line). Results represent means7SD from three
experiments. At 0 mM glucose the value for low and high
passage MIN-6 cells was 7.5 and 9.8, respectively, at 3.3 mM: 9.2
and 9.4, at 10 mM: 22.8 and 10.8, at 16.7 mM: 43.4 and 12.6, at
26.7 mM: 46.2 and 12.8. All values are in pmol/mL/mg protein
(pro(insulin)).
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were filtered out. The analysis was used to rapidly calculate
abundance differences between samples run on the same
gel. The biological variation analysis mode of DeCyder was
then used to match all pairwise image comparisons from
difference in-gel analysis for a comparative cross-gel
statistical analysis. Operator intervention was required at
this point to set landmarks on gels for more accurate cross-
gel image superimposition. Comparison of normalized Cy3
and Cy5 spot volumes with the corresponding Cy2 standard
spot volumes within each gel gave a standardized abun-
dance. This value was compared across all gels for each
matched spot and a statistical analysis was performed.
The differentially expressed proteins passed certain
criteria for inclusion in the list, including appearing in all
gels and a p-value of o0.01 (Table 2). Hemoglobin alpha
chain (spot 1) was found to be 8.45-fold increased, respec-
tively, in the media conditioned by the glucose non-
responsive MIN-6 beta cells compared to the responsive
phenotype (Fig. 3 and Table 2). Secretogranin II and
secretogranin III were identified in the CM from the MIN-6
cells. Secretogranin II (spots 2–4) and Secretogranin III
(spots 5–7) were both found to exist as clusters of isoforms
on the 2D gel. All isoforms for both proteins were found to
be significantly increased in the media conditioned by the
glucose-non-responsive MIN-6 beta cells compared with the
responsive phenotype (Fig. 3 and Table 2). The isoforms of
secretogranin III was found to have a greater average
ratio (12.85, 19.62, 15.63) respectively, compared with
those of secretogranin II (10.31, 10.88, 11.73), respectively,
in the CM.
The trend was similar in all three isoforms of TTR
reported in this paper, with an approximate 30-fold increase
in all isoforms, 32.93-fold increase in isoforms 1 (spot 8),
34.93-fold increase in isoforms 2 (spot 9), and a 27.11-fold
increase in isoforms 3 (spot 10) in the CM from the glucose-
non-responsive cells compared with the glucose-responsive
cells (Fig. 3 and Table 2).
Details on protein identifications are included in
Table 3. In total, hemoglobin was identified with 49% (six
matched peptides) coverage, secretogranin II 17% (eight
matched peptides), TTR 47% (six matched peptides), and
secretogranin III 15% (six matched peptides). All protein
identifications were confirmed from three separate
preparative gels. Careful visual inspection of the MALDI-
TOF-MS data showed peaks corresponding to peptides from
addition proteins. The relative intensities measured from
the MALDI-TOF-MS data were consistent with the claim
that the protein identified is the most abundant protein
within the spot. The minor protein components contributed
less than 5% of the total abundance of the mixture and will
have minimal effects on the quantification of the major
component (Fig. 4).
Table 2. Identification, average ratio, and t-test scores for proteins found to have different abundance levels in MIN-6(H) CM compared
with MIN-6(L) CMa)
Spot no. Protein ID Gene index no. t-test Av. ratio pI Mw (Da)
1 Hemoglobin alpha chain (Bos taurus) gi|6006423| 6.30E11 8.45 8.1 15 140
2 Secretogranin II (Mus musculus) gi|29387070| 2.60E07 10.31 4.6 66 350
3 Secretogranin II (Mus musculus) gi|29387070| 1.60E11 10.88 4.6 66 350
4 Secretogranin II (Mus musculus) gi|29387070| 2.10E07 11.73 4.6 66 350
5 Secretogranin III (Mus musculus) gi|74226380| 3.60E10 12.85 4.8 53 310
6 Secretogranin III (Mus musculus) gi|74226380| 6.50E11 19.62 4.8 53 310
7 Secretogranin III (Mus musculus) gi|74226380| 1.50E10 15.63 4.8 53 310
8 Ttr protein (Mus musculus) gi|19354093| 6.20E11 32.93 5.8 15 870
9 Ttr protein (Mus musculus) gi|19354093| 1.50E11 34.93 5.8 15 870
10 Ttr protein (Mus musculus) gi|19354093| 1.40E10 27.11 5.8 15 870
a) All proteins abundance levels were found to be substantially increased in the CM from MIN-6(H)/glucose-non-responsive cells
compared with MIN-6(L)/glucose responsive cells.
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Figure 3. 2-D-DIGE gel showing Cy2 signal obtained from a total
of 50 mg of MIN-6 CM proteins and analyzed using minimal
labeling. 2-D-DIGE gel shows the separation of proteins by
molecular weight and pI. Displayed on the gel are the locations
of the proteins of interest highlighted in this study. The
numbered proteins relate to Table 2, providing information on
protein identification, average ratio, and t-test scores for
proteins found to have different abundance levels in MIN-6(H)
CM compared with MIN-6(L) CM.
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3.4 Western blot analysis of secretogranin III and
TTR
Western blot analysis of secretogranin III and TTR
confirmed the results from the 2-D DIGE experiment
(Fig. 5). Results indicate a substantial increase in the
abundance levels of secretogranin III and TTR in the CM
from glucose-non-responsive MIN-6 beta cells compared to
the responsive phenotype.
4 Discussion
In this study, a 2-D DIGE and mass spectrometry approach
was utilized to analyze the CM from glucose-responsive and
glucose-non-responsive MIN-6 cells, a model for studying
beta cell dysfunction. Potential markers of beta cell
dysfunction secreted or shed into the circulatory system
are very likely to be at an extremely low concentration
making detection and analysis difficult. Secreted and shed
proteins accumulate in CM making their analysis by various
proteomics techniques and identification through mass
spectrometry more achievable. Irregular and abnormal
secretion or shedding of proteins is commonly associated
with disease, including diabetes [12]. Many of the proteins
highlighted in this study are potentially useful to investigate
as circulating serum biomarkers for beta cell dysfunction. In
this study we examined the secretome from glucose-
responsive MIN-6 beta cells compared with glucose-non-
responsive MIN-6 beta cells in order to identify proteins
indicative of beta cell dysfunction and defects in the
secretory machinery.
Granins (chromogranins or secretogranins) are a
family of acidic proteins present in the secretory granules
Table 3. Details on protein identifications are included in this
tablea)
Protein Matched peptides
Hemoglobin alpha chain
(Bos taurus)
VDPVNFK
MFLSFPTTK
FLANVSTVLTSK
VGGHAAEYGAEALER
TYFPHFDLSHGSAQVK
AVEHLDDLPGALSELSDLHAHK
Secretogranin II
(Mus musculus)
IILEALR
DQLSEDASK
FPSPEMIR
NEQINEEMK
QAENEPPSAPK
QYLDEDMLLK
ENGEESHLAESSR
EESSPDYNPYQGVSVPLQLK
Secretogranin III
(Mus musculus)
IYEENDR
LIDEYDSTK
TEAYLEAIR
EANNYEETLDKPTSR
SPPFDNQLNVEDADSTK
FQDDPDGLHQLDGTPLTAEDIVHK
Ttr protein
(Mus musculus)
FVEGVYR
GSPAVDVAVK
TSEGSWEPFASGK
TAESGELHGLTTDEK
TLGISPFHEFADVVFTANDSGHR
HYTIAALLSPYSYSTTAVVSNPQN
a) The details include protein name, species and matched
peptides associated with the protein. All protein identifi-
cations were confirmed from three separate preparative
gels.
Figure 4. The labeled peaks in this
spectrum all come from the identi-
fied protein, secretogranin II giving
approximately 17% coverage. The
non-secretogranin II peaks corre-
sponding to trypsin/acrylamide and
the others are such a low intensity
that their presence will not signifi-
cantly affect the positive identifica-
tion.
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(SG) of a wide variety of endocrine and neuro-endocrine
cells. Secretogranin II (SgII), together with chromo-
granins A (CgA) and B (CgB), makes up the major members
of this group of proteins. Secretogranins III–VII are also
members of the granin family but less is known about
these [13, 14]. Secretogranins are the precursors of several
bioactive peptides, including secretoneurin, a peptide
generated from SgII [15]. These proteins do not share
many structural similarities but do have similar subcellular
locations. Studies in rodents suggest that the full-length
protein, secretogranin II, is involved in the packaging or
sorting of peptide hormones and neuropeptides
into secretory vesicles. SgIII tends to localize in the vicinity
of SG membranes, as revealed by electron microscopic
Figure 5. Statistical analysis, gel image, and 3-D images for Scg III (secretogranin III) and TTR in CM from MIN-6 cells. Statistical analysis
and 3-D images were generated in the BVA module of DeCyder software. Three isoforms of Scg III were found to be 12.85-, 19.62-, and
15.63-fold increased, respectively, in the CM from MIN-6(H) compared with MIN-6(L). Displayed are images for the 19.62-fold increased
isoform. Results from 2-D DIGE analysis for Scg III were confirmed by Western blot analysis as shown. Three isoforms of TTR were found
to be 32.93-, 34.93-, and 27.11-fold increased, respectively, in the CM from MIN-6 (H) compared with MIN-6 (L). Displayed are images for
the 34.93-fold increased isoform. Results from 2-D DIGE analysis for TTR were confirmed by Western blot analysis as shown.
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observation. There is also evidence to suggest that SgIII and
CgB are closely associated with the SG membrane and that
this membrane association might contribute to gathering
and anchoring of other soluble constituents to the SG
membrane [16–18].
Our results show a substantial increase in the abun-
dance levels for clusters of isoforms from both SgII and
SgIII in media conditioned by glucose-responsive and
glucose-non-responsive MIN-6 cells. These results indicate a
large release of the SG proteins SgII and SgIII from MIN-6
beta cells that are dysfunctioning and not secreting insulin
in response to glucose stimulation. SgII and SgIII are very
much part of SG biogenesis and the massive release of these
proteins indicates that the granules are no longer func-
tioning normally.
TTR, formerly called prealbumin, was first identified in
1942 by Kabat in serum and cerebrospinal fluid and
belongs to a group of proteins including thyroxine-binding
globulin and albumin, which bind to and transport thyroid
hormones in the blood, usually occurring at a concentration
of 200–400mg/L in serum [19]. TTR is synthesized in the
liver, the choroid plexus of the brain, and the endocrine
pancreas [20]. Serum levels of TTR, however, are also
affected by acute and chronic diseases associated with an
acute-phase response [20]. Sundsten and co-workers repor-
ted that TTR was up-regulated in serum from type II
diabetes individuals compared with normal glucose toler-
ance individuals using protein profiling by SELDI-TOF MS
[21]. Refai and co-workers recently demonstrated that the
TTR tetramer has a positive role in pancreatic beta-cell
stimulus-secretion coupling. TTR promoted glucose-
induced increases in cytoplasmic free calcium concentration
and insulin release [22]. Also reported was that the
concentration of the TTR tetramer was decreased, whereas
that of a monomeric form was increased in sera from
patients with type I diabetes. The monomer was without
effect on glucose-induced insulin release and apoptosis.
Thus, TTR tetramer constitutes a component in normal
beta-cell function. Conversion of TTR tetramer to monomer
may be involved in the development of beta-cell failure/
destruction in type I diabetes.
These results published by Refai and co-workers are
supported by results presented in this paper [22]. The
levels of TTR monomer was found to be substantially
increased in the CM from the high-density glucose-non-
responsive cells compared with the glucose-responsive cells.
We also describe values for three isoforms of TTR found on
the 2-D gel. The trend was similar in all three isoforms
reported in this paper, with an approximate 30-fold increase
in all isoforms.
Hemoglobin alpha chain was also found to be signifi-
cantly increased in the CM from the glucose-non-responsive
MIN-6 beta cells. Hemoglobin alpha chain together with the
beta chain has already been proposed as biomarkers for
ovarian cancer [23]. Interestingly in this case, hemoglobin
alpha chain was found to be the bovine form indicating that
the glucose-non-responsive cells were absorbing more of
this protein when grown in standard conditions with FCS in
the media.
It is also interesting to note that some groups are
developing biomarkers based on protein isoforms and also
the ratios of protein isoforms detected in particular diseases.
However, with up to 30 000 or more protein variants in a
single cell, protein isoform differentiation and measure-
ment has been a major challenge in the development of
clinical diagnostic assays [24–26].
We also examined CM from glucose-responsive and
glucose-non-responsive MIN-6 cells at both a medium
and high cell density in order to elucidate if cell density is a
big factor into the type and/or concentration of proteins
detected (results not shown). The abundance levels
for all the proteins highlighted in this study substantially
increased in the CM from the high density cells compared
with the medium density. These data show a direct corre-
lation with numbers of cells conditioning the medium and
the concentration of potential markers of beta cell
dysfunction. Cell-to-cell communication occurs in normal
functioning pancreatic beta-cells and it is worth considering
if different signals are transmitted in dysfunctioning
beta cells.
Novel biomarkers would have the potential to be used
for predicting beta cell function. A panel of biomarkers,
rather than individual markers, may be able to supply the
specificity and sensitivity required. The ultimate goal would
be the development of an assay, for example, an immu-
noassay (ELISA) that would detect each of the individual
proteins in the panel and allow for detection of beta cell
dysfunction and monitoring of specific therapies used in the
treatment of diabetes.
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